Research progress on clinical cardiovascular protective effect and mechanism of SGLT-2 inhibitors
- VernacularTitle:SGLT-2i临床心血管保护作用及机制研究进展
- Author:
Xue-wan GE
1
;
Yan WU
;
Mo GUO
;
Shan GAO
Author Information
- Publication Type:Journal Article
- Keywords: sodium-glucose cotransporter 2 inhibitor; heart fail-ure; cardiovascular protective effect
- From: Chinese Pharmacological Bulletin 2025;41(3):401-406
- CountryChina
- Language:Chinese
- Abstract: Sodium-glucose cotransporter 2 inhibitor was initially developed and marketed as a novel oral hypoglycemic agent.Currently,it has been recommended as one of the main therapeu-tic agents for chronic heart failure by national and international guidelines,and it has a significant cardioprotective effect on heart failure with reduced ejection fraction,heart failure with im-proved ejection fraction,heart failure with mildly reduced ejec-tion fraction,and heart failure with preserved ejection fraction.However,cardiac tissues do not express sodium-glucose cotrans-porter 2,and the underlying mechanisms of clinical cardiovascu-lar benefits of sodium-glucose cotransporter 2 inhibitors remain unclear.This review intends to summarize the cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in clinical trials and the recommendations suggested by national and inter-national heart failure guidelines and to elucidate further the po-tential mechanisms of sodium-glucose cotransporter 2 inhibitor-mediated cardioprotective effects.
